Intelligence Feed event · Policy · 2026-09-29

    AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer

    Question

    AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer

    Direct answer

    HUTCHMED announced that commercial partner AstraZeneca submitted an NDA to the US Food and Drug Administration for the oral MET inhibitor savolitinib combined with osimertinib. The regimen is indicated for patients with MET-amplified, EGFR-mutated non-small cell lung cancer exhibiting resistance to first-line EGFR tyrosine kinase inhibitors. The regulatory filing represents a critical commercial milestone for HUTCHMED under its global development agreement with AstraZeneca, expanding savolitinib's geographic commercial footprint into the US oncology market.

    Original publisher
    Market Ontology
    Evidence through
    2026-09-29
    Published
    2026-10-20
    Revision
    1 · 2026-10-20

    Cite as: Market Ontology, “AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer”, revision 1, evidence through 2026-09-29. https://marketontology.com/market-events/2026-09-29/astrazeneca-and-hutchmed-submit-us-nda-for-orpathys-plus-tagrisso-in-lung-cancer-c2eafe

    POLICY
    AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer
    HUTCHMED announced that commercial partner AstraZeneca submitted an NDA to the US Food and Drug Administration for the oral MET inhibitor savolitinib combined with osimertinib. The regimen is indicated for patients with MET-amplified, EGFR-mutated non-small cell lung cancer exhibiting resistance to first-line EGFR tyrosine kinase inhibitors. The regulatory filing represents a critical commercial milestone for HUTCHMED under its global development agreement with AstraZeneca, expanding savolitinib's geographic commercial footprint into the US oncology market.
    HCMAZN
    Impact
    68
    SEP 29
    SIG
    92%
    HCMAZN
    AstraZeneca and HUTCHMED Submit US NDA for ORPATHYS Plus TAGRISSO in Lung Cancer
    HUTCHMED announced that commercial partner AstraZeneca submitted an NDA to the US Food and Drug Administration for the oral MET inhibitor savolitinib combined with osimertinib. The regimen is indicated for patients with MET-amplified, EGFR-mutated non-small cell lung cancer exhibiting resistance to first-line EGFR tyrosine kinase inhibitors. The regulatory filing represents a critical commercial milestone for HUTCHMED under its global development agreement with AstraZeneca, expanding savolitinib's geographic commercial footprint into the US oncology market.
    → FDA NDA acceptance initiates the formal regulatory review timeline for savolitinib, creating milestone royalty expansion for HCM and line extension defense for AZN.
    Impact
    HUTCHMED announced that commercial partner AstraZeneca submitted an NDA to the US Food and Drug Administration for the oral MET inhibitor savolitinib combined with osimertinib. The regimen is indicated for patients with MET-amplified, EGFR-mutated non-small cell lung cancer exhibiting resistance to first-line EGFR tyrosine kinase inhibitors. The regulatory filing represents a critical commercial milestone for HUTCHMED under its global development agreement with AstraZeneca, expanding savolitinib's geographic commercial footprint into the US oncology market.
    Affected
    HCMAZN
    Transmission
    FDA NDA acceptance initiates the formal regulatory review timeline for savolitinib, creating milestone royalty expansion for HCM and line extension defense for AZN.

    How this development reaches the affected companies

    AssetExposure and channelDirectionEvidence
    HCMregulatory milestone achievement and future US commercial royaltiesUp1-3mAstraZeneca submitted US NDA for ORPATHYS plus TAGRISSO in MET-driven EGFR-mutated lung cancer
    AZNTAGRISSO franchise extension via combination therapyUp1-3mUS NDA submission to treat lung cancer patients who progressed on EGFR-TKI therapy

    Does this development affect your holdings?

    Enter your holdings to check them against this and other recent developments, review the decision that matters most, then set a monitor.

    Check this development against my holdings

    Review your initial audit before choosing ongoing portfolio scanning at $79/month.

    What happened next

    AssetCallBase close+1 day+5 days+20 days
    HCMUpagreed14.15 2026-09-29+3.39%PendingPending

    Closing prices from stored daily bars; returns measured from the last close on or before the event date. Not a recommendation.

    No verifiable public source recorded for this card.

    Related

    Check this development against my holdings

    See today's live cards

    Public pages are published 24 hours after the product shows them. Desk shows every catalyst, event and causal reading as it happens, mapped to your holdings.

    Open Desk — $399/month